King of Prussia, PA · Founded 2013 · Privately Held (backing)
Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease. XyloCor Therapeutics is based in King of Prussia, PA and was founded in 2013. It was valued at $130 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $122 million across 3 recorded rounds; the latest was a $4 million seed round in Jan 2021.
PMV mark · valuation
$130.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$122.0M
Last round
Seed Round
Jan 2021
No prints on record
No secondary trades in XyloCor Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of XyloCor Therapeutics with a free account
·Watch XyloCor Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of XyloCor Therapeutics stock.
